BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP